Exosome therapy for mild to moderate Alzheimer's disease
Part of Brain & nervous system clinical trials.
This trial tests a new drug made from stem cell exosomes (CB-Exo-A600) to see if it can help people with mild to moderate Alzheimer's disease. It aims to slow down symptoms and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 50 years or older.
- Have mild to moderate Alzheimer's disease (with a diagnosis confirmed by spinal fluid, PET scan, or blood test within the last 3 years).
- Have a recent MRI or CT scan showing changes consistent with Alzheimer's and no other major brain problems.
- Score between 10 and 24 on a memory and thinking test (MMSE).
- Have a reliable caregiver who lives with you or helps you at least 2 hours a day, 3 days a week.
- Be on stable doses of Alzheimer's medications (like donepezil or memantine) for at least 60 days before starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a nasal drop made from tiny cell particles (extracellular vesicles) for ALS. The goal is to see if it's safe and if it can slow down the disease. It may be an option if your ALS is in the early to moderate stage.
This trial tests a new nasal drop treatment made from stem cells for people with Alzheimer's, Parkinson's, multiple system atrophy, Lewy body dementia, frontotemporal dementia, or ALS. The drops may help slow disease progression by delivering tiny healing particles directly to the brain through the nose.
This study tests whether tiny particles called exosomes derived from neural stem cells can help slow memory loss and thinking problems in people with Alzheimer's disease that started before age 65. The treatment is given through the nose and aims to reduce harmful proteins in the brain.
This trial tests whether exosomes (tiny particles from stem cells) can help slow or improve symptoms of frontotemporal dementia, a disease affecting thinking and behavior. You would receive the treatment and be monitored to see if it helps.
This trial tests a new stem cell treatment (called RB-ADSCs) that is injected into the fluid around your brain. It aims to see if these cells can help slow down memory loss and thinking problems in people with mild to moderate Alzheimer's disease.
This trial tests a stem cell treatment for people with early-stage Alzheimer's disease. It aims to see if the treatment can help slow memory loss or other symptoms. You must have a specific blood test showing inflammation in the body to qualify.
Hear when a new Mild to Moderate Alzheimer's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.